FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
I	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_													
1. Name and Address of Reporting Person* <u>CARLOZZI GERARD S</u>					<u>IN</u>	2. Issuer Name and Ticker or Trading Symbol  INTEGRA LIFESCIENCES HOLDINGS  CORP [ IART ]								eck all applic Directo	able) r	eporting Person(s) to Issuer e) 10% Owner		
(Last) 311 ENT	ast) (First) (Middle)				3.	3. Date of Earliest Transaction (Month/Day/Year) 12/31/2003								X Officer (give title Other (specify below)  Exec VP, COO				
(Street) PLAINSBORO NJ 08536					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City)	(	•	(Zip)															
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					action	tion 2A. Deemed Execution Date, if any		3. 4. Securities		of, or Beneficians as Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ion(s)		1	(Instr. 4)
Common Stock 12/31/20				′2003 <sup>(</sup>	003 <sup>(1)</sup> 12/31/2003		I		335	A	\$24.04	55 3	335		D			
			Table II								oosed of, convertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security		3A. Deem Executior if any (Month/Da	Date,	4. Transa Code ( 8)		of I		6. Date Exercis. Expiration Date (Month/Day/Yea		е	7. Title and of Securiti Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s F lly D o (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code		(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amount or Number of Shares					
Incentive Stock Option (right to buy)	\$28.78	01/02/2004	01/02/	2004	A		521		01/02/200	)5 <sup>(2)</sup>	01/02/2010	Common Stock	521	\$0.00	521		D	
Non- Qualified Stock Option (right to	\$28.78	01/02/2004	01/02/	2004	A		24,479		01/02/200	)5 <sup>(2)</sup>	01/02/2010	Common Stock	24,479	\$0.00	24,479	9	D	

## Explanation of Responses:

- 1. Shares acquired pursuant to Integra LifeSciences' 1998 Employee Stock Purchase Plan under Section 423 of the Internal Revenue Code of 1986, as amended, in a transaction exempt under Rule 16b-3.
- 2. 25% of the options vest one year after the grant date, with the remaining 75% vesting monthly thereafter 36 months.

/s/ Gerald S. Carlozzi

01/05/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.